EUVIMEDSkopri EUVIMED
Crossref

Plasma kinetics of mitoxantrone in leukemic patients

R Hulhoven, E Dumont, C Harvengt

Medical Oncology and Tumor Pharmacotherapy · 1984

DOI: 10.1007/bf02934142 ↗

At a glance

Journal article in Medical Oncology and Tumor Pharmacotherapy, 1984. Written by R Hulhoven and 2 co-authors. Cited 5 times so far (Crossref); 16 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The plasma kinetics of mitoxantrone (MX), a new cytostatic anthracenedione, were investigated with HPLC in five leukemic patients suffering from acute myeloid leukemia, at the dose of 24 mg m-2 infused over 30 min at constant rate. The decay of the plasma concentrations was best fitted to a three compartment model with average elimination half-lives of respectively 4.1 min (alpha-phase), 19.8 min (beta-phase) and 8.9 h (gamma-phase), a mean distribution volume of 317 l m-2 and an average total body clearance of 0.37 l min-1 m-2. The cumulative urinary recovery of unchanged MX was 7.5% of the administered dose in 4 days, with the highest elimination during the first day. No MX urinary metabolites or conjugates have been detected.

Subjects

MeSH terms (MEDLINE)

AnthraquinonesAntineoplastic AgentsHumansKineticsLeukemiaMitoxantrone

Substances

AnthraquinonesAntineoplastic AgentsMitoxantrone

Cite

APA

Hulhoven, R., Dumont, E., & Harvengt, C. (1984). Plasma kinetics of mitoxantrone in leukemic patients. Medical Oncology and Tumor Pharmacotherapy. https://doi.org/10.1007/bf02934142

Vancouver

Hulhoven R, Dumont E, Harvengt C. Plasma kinetics of mitoxantrone in leukemic patients. Medical Oncology and Tumor Pharmacotherapy. 1984. doi:10.1007/bf02934142

BibTeX
@article{Hulhoven1984,
  author = {Hulhoven, R and Dumont, E and Harvengt, C},
  title = {Plasma kinetics of mitoxantrone in leukemic patients},
  journal = {Medical Oncology and Tumor Pharmacotherapy},
  year = {1984},
  doi = {10.1007/bf02934142}
}
Start for free →